Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266405 | 0.76 | CSNK2A1 (0.50) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL1692228 | 0.74 | BUB1 (0.65) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL23346919 | 0.73 | — | — | |
| SCHEMBL31471536 | 0.72 | CSNK2A1 (0.42) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL13422040 | 0.72 | CSNK2A1 (0.42) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL31471533 | 0.72 | CSNK2A1 (0.42) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL31471525 | 0.72 | CSNK2A1 (0.42) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL13415965 | 0.71 | BRD4 (0.44) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL13415967 | 0.71 | CSNK2A1 (0.43) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 | |
| SCHEMBL13477016 | 0.71 | HPGD (0.43) | CSNK2A1PLK1PLK3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | CSNK2A1 2539/4885PLK1 4824/4885PLK3 4664/4885 |
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | SIGMAR1, TMEM97, OPRK1 | CSNK2A1 71/4885PLK1 4859/4885PLK3 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.